A recent study indicates that tocilizumab, a medication primarily used for rheumatoid arthritis, could provide a new treatment option for individuals with difficult-to-treat depression. Traditional antidepressants target brain chemicals, but about one in three patients do not find relief. Conducted by researchers at the University of Bristol, the trial involved 30 participants with moderate-to-severe depression, revealing that tocilizumab might alleviate depressive symptoms, reduce fatigue and anxiety, and enhance overall quality of life. This research builds on evidence that approximately one-third of individuals with depression show inflammation markers, suggesting a link between depression and an overactive immune response. The trial, which divided participants into two groups—one receiving tocilizumab and the other a placebo—showed that those treated with tocilizumab had more significant improvements. Senior author Professor Golam Khandakar emphasized the study's importance in developing new treatments for depression, particularly for those who do not respond to standard therapies. The next step involves conducting a larger phase III trial to solidify these findings and potentially enable doctors to prescribe immunotherapy for depression.